Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) – Pipeline Review, H2 2017’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders under development targeting Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)

The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects

The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Abeome Corp

Alligator Bioscience AB

Apogenix GmbH

BioInvent International AB

Bristol-Myers Squibb Company

Denceptor Therapeutics Ltd

Enumeral Biomedical Holdings Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Incyte Corp

Kyowa Hakko Kirin Co Ltd

MedImmune LLC

Pfizer Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Overview 7

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 13

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Assessment 17

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Companies Involved in Therapeutics Development 23

Abeome Corp 23

Alligator Bioscience AB 23

Apogenix GmbH 24

BioInvent International AB 24

Bristol-Myers Squibb Company 25

Denceptor Therapeutics Ltd 25

Enumeral Biomedical Holdings Inc 26

GlaxoSmithKline Plc 26

Glenmark Pharmaceuticals Ltd 27

Incyte Corp 27

Kyowa Hakko Kirin Co Ltd 28

MedImmune LLC 28

Pfizer Inc 29

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drug Profiles 30

ATOR-1015 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

BMS-986178 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

durvalumab + MEDI-0562 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

ENUM-004 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Fusion Proteins to Agonize OX40 and NOTCH1 for Type 1 Diabetes - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

GBR-8383 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

GSK-3174998 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

INCAGN-1949 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

KHK-4083 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

MEDI-0562 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

MEDI-0562 + tremelimumab - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Monoclonal Antibody Conjugate to Target OX40L for Transplant Rejection - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Monoclonal Antibody to Agonize OX40L Receptor for Oncology - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

PF-04518600 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Recombinant Protein to Agonize OX40 for Solid Tumor - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

ZL-1101 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Dormant Products 49

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Discontinued Products 50

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Product Development Milestones 51

Featured News & Press Releases 51

Jul 08, 2017: Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015 51

May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ATOR-1015 51

Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4 51

Mar 07, 2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 52

Nov 30, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors 52

Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN-1949 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 53

Nov 03, 2015: GSK and Merck to study immunotherapy combination as potential cancer treatment 53

Sep 21, 2011: AgonOx Receives US Patent For OX40 Ligand Fusion Proteins And Use In Cancer Therapy 54

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 16

Number of Products by Stage and Mechanism of Actions, H2 2017 18

Number of Products by Stage and Route of Administration, H2 2017 20

Number of Products by Stage and Molecule Type, H2 2017 22

Pipeline by Abeome Corp, H2 2017 23

Pipeline by Alligator Bioscience AB, H2 2017 23

Pipeline by Apogenix GmbH, H2 2017 24

Pipeline by BioInvent International AB, H2 2017 24

Pipeline by Bristol-Myers Squibb Company, H2 2017 25

Pipeline by Denceptor Therapeutics Ltd, H2 2017 25

Pipeline by Enumeral Biomedical Holdings Inc, H2 2017 26

Pipeline by GlaxoSmithKline Plc, H2 2017 26

Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017 27

Pipeline by Incyte Corp, H2 2017 27

Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 28

Pipeline by MedImmune LLC, H2 2017 28

Pipeline by Pfizer Inc, H2 2017 29

Dormant Projects, H2 2017 49

Discontinued Products, H2 2017 50

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 17

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Routes of Administration, H2 2017 19

Number of Products by Stage and Routes of Administration, H2 2017 19

Number of Products by Molecule Types, H2 2017 21

Number of Products by Stage and Molecule Types, H2 2017 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports